Edison issues review on Worldwide Healthcare Trust
London, UK, 28 January 2022
Edison issues review on Worldwide Healthcare Trust (WWH)
Worldwide Healthcare Trust (WWH) is managed by Sven Borho and Trevor Polischuk at healthcare specialist investor OrbiMed. While disappointed with the trust's performance in 2021, the managers are upbeat about its prospects in 2022 based on their expectation for a reversal in the underperformance of biotech and Chinese stocks, due to positive industry fundamentals including high levels of innovation. Also, clarity in drug pricing reform could lead to an improvement in investor sentiment towards the healthcare sector. Borho and Polischuk are anticipating an uptick in mergers and acquisitions (M&A) this year, compared with muted levels in 2021, which should provide further support for healthcare stocks.
WWH's board employs a discount control mechanism aiming to ensure a maximum 6% share price discount to ex-income NAV in normal market conditions. The trust's shares are currently trading at a 1.7% discount to its cum-income NAV, which compares to average premiums of 0.0%, 0.1% and 0.1% over the last one, three and five years, respectively. In FY21, WWH's share base increased by about 20%, which raised £380.6m, and so far in FY22, a further c 1.2m shares (c 1.9% of the share base) have been issued, raising c £45.6m.
Click here
to view the full report or
here
to sign up to receive research as it is published.
All reports published by Edison are available to download free of charge from its website
About Edison: E dison is a leading research and investor relations consultancy, connecting listed companies to the widest pool of global investors. By focusing on the volume and quality of investors reached - across institutions, family offices, wealth managers and retail investors - Edison can create and gauge intent to purchase, even in the darkest pools of capital, and then make introductions via non-deal roadshows, events or virtual meetings.
Having been the first in-market 17 years ago, Edison now has more than 100 analysts covering every economic sector. Headquartered in London, Edison also has offices in New York, Frankfurt, Amsterdam and Tel Aviv and a presence in Athens, Johannesburg and Sydney.
Edison is authorised and regulated by the Financial Conduct Authority .
Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.
For more information, please contact Edison:
Mel Jenner +44 (0)20 3077 5720 investmenttrusts@edisongroup.com
Sarah Godfrey +44 (0)20 3681 2519 investmenttrusts@edisongroup.com
Learn more at www.edisongroup.com and connect with Edison on:
LinkedIn www.linkedin.com/company/edison-group-/
Twitter www.twitter.com/Edison_Inv_Res
YouTube www.youtube.com/edisonitv
Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 1 hour ago Touchstone Exploration Inc NPV (DI)
- 1 hour ago Diaceutics
- 1 hour ago Taseko Mines Limited NPV (DI)
- 1 hour ago Taseko Mines Limited NPV (DI)
- 1 hour ago Arecor Therapeutics